Dr. Ignacio Iturbe, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
855 3rd Ave Ste 3330
Chula Vista, CA 91911
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 54
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 150
Licensed in California since 1985, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A42415 (first issued 1985; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Scripps Mercy Hospital San Diego, CA
- Sharp Chula Vista Medical Center Chula Vista, CA
Medical groups
- Emergency and Acute Care Medical Corporation (422 clinicians)
- On Call Specialists Medical Group of San Diego Inc (144 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 150
- Services billed
- 462
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 270 | 105 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 57 | 27 |
| New patient office or other outpatient visit, 45-59 minutes | 41 | 41 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 21 | 21 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 21 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Chula Vista, CA | 31 |
| Letrozole Other prescribers in Chula Vista, CA | 23 |
| Jakafi (ruxolitinib phosphate) | 21 |
| Warfarin Sodium Other prescribers in Chula Vista, CA | 18 |
| Revlimid (lenalidomide) | 17 |
| Pantoprazole Sodium Other prescribers in Chula Vista, CA | 17 |
| Tasigna (nilotinib hcl) | 17 |
| Calquence (acalabrutinib maleate) | 16 |
| Lenalidomide | 16 |
| Brukinsa (zanubrutinib) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 36 companies reported 119 payments worth $3,073 in total to this clinician.
| Merck Sharp & Dohme LLC | $346 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $328 |
| Janssen Biotech, Inc. | $277 |
| Novartis Pharmaceuticals Corporation | $210 |
| Sobi, Inc | $193 |
| Pfizer Inc. | $184 |
| AbbVie Inc. | $165 |
| Beone Medicines USA, Inc. | $152 |
| Food and Beverage | $2,973 |
|---|---|
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 1, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.